279 related articles for article (PubMed ID: 24748377)
1. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Szabova L; Bupp S; Kamal M; Householder DB; Hernandez L; Schlomer JJ; Baran ML; Yi M; Stephens RM; Annunziata CM; Martin PL; Van Dyke TA; Weaver Ohler Z; Difilippantonio S
PLoS One; 2014; 9(4):e95649. PubMed ID: 24748377
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.
Szabova L; Yin C; Bupp S; Guerin TM; Schlomer JJ; Householder DB; Baran ML; Yi M; Song Y; Sun W; McDunn JE; Martin PL; Van Dyke T; Difilippantonio S
Cancer Res; 2012 Aug; 72(16):4141-53. PubMed ID: 22617326
[TBL] [Abstract][Full Text] [Related]
4. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
6. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
7. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
10. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
12. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
13. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
15. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
16. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.
Tsofack SP; Meunier L; Sanchez L; Madore J; Provencher D; Mes-Masson AM; Lebel M
BMC Cancer; 2013 Jun; 13():303. PubMed ID: 23800275
[TBL] [Abstract][Full Text] [Related]
17. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract][Full Text] [Related]
18. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
20. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC
Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
